test

Clinical Trials

Bladder Cancer

10
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Disease/Condition: Bladder | Cancer
Principal Investigator: Hari Deshpande
An Open-label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second line Therapy in Patients With Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Disease/Condition: Bladder | Kidney | Other Urinary
Principal Investigator: Daniel Petrylak
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Disease/Condition: Bladder | Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Transitional Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer
Principal Investigator: Hari Deshpande

Kidney Cancer

Prostate Cancer

10
A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) whose Disease has Progressed after Docetaxel Chemotherapy
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Brain and Nervous System | Breast - Female | Breast - Male | Breast Cancer (ER, PR, and HER2 negative) | Colon | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Lip, Oral Cavity and Pharynx | Lung | Melanoma | Melanoma, skin | Non-Small Cell Lung Cancer (NSCLC) | Other Female Genital | Ovarian Cancer | Ovary | Prostate | Prostate Cancer | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase II Open Label Multicenter Study of PSMA ADC in Subjects with Castration-resistant Metastatic Prostate Cancer
Disease/Condition: Cancer | Prostate
Principal Investigator: Daniel Petrylak
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized Phase III Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized, Open-Label, Phase II Study of Sipuleucel-T with Concurrent vs Sequential Administration of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Disease/Condition: Bladder | Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Transitional Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer
Principal Investigator: Hari Deshpande
RTOG 0815: Randomized Trial With or Without Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer
Disease/Condition: Prostate | Prostate Cancer
Principal Investigator: Joseph Cardinale